It Seems Adaptimmune Therapeutics Plc – American Depositary (NASDAQ:ADAP) Will Go Down. Just Reported More Shorted Shares

June 16, 2018 - By Ash

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Logo

The stock of Adaptimmune Therapeutics Plc – American Depositary (NASDAQ:ADAP) registered an increase of 19.74% in short interest. ADAP’s total short interest was 1.45M shares in June as published by FINRA. Its up 19.74% from 1.21 million shares, reported previously. With 362,500 shares average volume, it will take short sellers 4 days to cover their ADAP’s short positions. The short interest to Adaptimmune Therapeutics Plc – American Depositary’s float is 3.15%.

The stock increased 2.12% or $0.26 during the last trading session, reaching $12.51. About 398,602 shares traded. Adaptimmune Therapeutics plc (NASDAQ:ADAP) has risen 151.13% since June 16, 2017 and is uptrending. It has outperformed by 138.56% the S&P500.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. The company has market cap of $1.18 billion. The Company’s platform enables to identify cancer targets; find and genetically engineer T-cell receptors ; and produce TCR therapeutic candidates for administration to patients. It currently has negative earnings. The companyÂ’s lead program includes NY-ESO-1 and LAGE-1a cancer antigens, which are in Phase I/II clinical trials for patients with solid tumors, as well as hematological cancer types, including synovial sarcoma, multiple myeloma, non-small cell lung cancer (NSCLC), and ovarian cancer; and pilot trial for myxoid round cell liposarcoma.

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Ratings Coverage

Among 3 analysts covering Adaptimmune Therapeutics (NASDAQ:ADAP), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adaptimmune Therapeutics had 3 analyst reports since March 16, 2018 according to SRatingsIntel. The rating was initiated by Leerink Swann on Friday, March 16 with “Buy”. As per Friday, March 16, the company rating was maintained by Cowen & Co.

More news for Adaptimmune Therapeutics plc (NASDAQ:ADAP) were recently published by:, which released: “Investor Expectations to Drive Momentum within SK Telecom Co., Adaptimmune Therapeutics, Fiat Chrysler …” on June 01, 2018.‘s article titled: “Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self-renewing, and …” and published on June 11, 2018 is yet another important article.

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: